Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening

Prostate

Volumn 40, Issue 1, 1999, Pages 56-61

  Horninger, Wolfgang ^a   Rogatsch, H ^b   Reissigl, A ^a   Volgger, H ^a   Klocker, H ^a   Hobisch, A ^a   Bartsch, G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Pathologic stage; Preoperative predictors; PSA screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0033564529     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990615)40:1<56::AID-PROS7>3.0.CO;2-E     Document Type: Article

References (27)

1. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, MacFarlane MT, Southwick PC. Comparison of digital rectal examination and serum prostate specific antigen in the detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
2. Reissigl A, Horninger W, Fink K, Klocker H, Bartsch G. Prostate carcinoma screening in the county of Tyrol, Austria: experience and results. Cancer 1997;80:1818-1829.
3. Reissigl A, Klocker H, Fink K, Horninger W, Bartsch G. Usefulness of the ratio free/total PSA in addition to total PSA levels in prostate cancer screening. Urology 1996;48:62-66.
4. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
5. Horninger W, Reissigl A, Klocker H, Rogatsch H, Fink K, Strasser H, Bartsch G. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate 1998;37:133-137.
6. Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989;141:1070-1075.
7. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076-1083.
8. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989;142: 1011-1017.
9. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-752.
10. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152:1732-1736.
11. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Liber MM. Serum prostate specific antigen in a community based population of healthy men. Establishment of age specific reference ranges. JAMA 1993;270:860-864.
12. Beahrs OH, Henson D, Hutter RVD, Kennedy BJ. Manual for staging of cancers, 4th ed. Philadelphia: J.B. Lippincott; 1992.
13. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-279.
14. Epstein JI, Walsh PC, Carminchael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
15. Rainwater LM, Morgan WR, Klee GG, Zinke H. Prostate specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin Proc 1990;65:1118-1126.
16. Partin AW, Yoo J, Carter HB, Pearson YD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
17. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, Brendler CB, Walsh PC. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J Urol 1988;139: 766-772.
18. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-879.
19. Henricks WH, England BG, Giacherio DA, Oesterling JE, Wojno KJ. Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J Urol 1996;155:369.
20. Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J Urol 1997;157:544-547.
21. Lerner SE, Jacobsen SJ, Lilja H, Bergstralh EJ, Ransom J, Klee GG, Piironen T, Blute ML, Lieber MM, Zincke H, Pettersson K, Peterson D, Oesterling JE. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 1996;48: 240-248.
22. Arcangeli CG, Shepherd DL, Smith DS, Humphrey PA, Keetch KW, Catalona WJ. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998;51:558-564.
23. Elgamal AA, Cornillie FJ, van Poppel HP, van de Voorede WM, McCabe R, Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol 1996;156:1042-1047.
24. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998;159:1238-1242.
25. Humphrey PA, Frazier HA, Vollmer RT, Paulson DF. Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum PSA levels. Cancer 1993;71:1821-1827.
26. Epstein JI, Partin AW, Saurageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analyses of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-292.
27. Kalish J, Cooner WH, Graham SD. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 1994;43:601-606.